癌症/腫瘤分析市場：按生物標記類型（基因、蛋白質），按技術，按癌症類型，按應用，按最終用戶劃分-到2030年的全球預測

癌症/腫瘤分析市場：依生物標記類型（基因、蛋白質）依技術（NGS、PCR、ISH、IHC）依癌症類型（乳癌、肺癌、大腸癌、攝護腺癌、白血病）依應用（臨床） 、研究）按最終用戶（製藥、學術、CRO）劃分 - 到 2030 年的世界預測

到 2030 年，全球癌症/腫瘤分析市場預計將達到 223 億美元，2023 年至 2030 年複合年增長率為 20.9%。

經過廣泛的二次和初步研究以及對市場情景的詳細分析，本報告對關鍵行業的驅動因素、限制因素、挑戰和機會進行了分析。 癌症/腫瘤分析市場的成長是由以下因素推動的：癌症盛行率的增加、藥物研發費用的增加、標靶治療數量的增加和新的可操作生物標記的發現、癌症研究投資的增加、 NGS 基於分析的成本不斷下降歸因於多組學腫瘤分析的進展。 然而，NGS 設定所需的高資本投資和長週轉時間限制了該市場的成長。

此外，日益關注個人化醫療開發、提高標靶治療的認識和採用預計將創造市場成長機會。 然而，缺乏解釋結果的遺傳學專家、缺乏內部腫瘤分析技術以及生物標記錯誤發現率高，給癌症/腫瘤分析市場的利害關係人帶來了重大挑戰。

目錄

第 1 章簡介

第 2 章研究方法

第 3 章執行摘要

第 4 章市場洞察

• 市場
• 摘要
• 影響市場成長的因素
  • 市場動態影響分析
  • 因素分析
• 監理分析
  • 北美
    • 美國
    • 日本
    • 印度
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 日本
    • 印度
  • 拉丁美洲
  • 中東
• 波特五力分析

第 5 章依生物標記類型評估癌症/腫瘤分析市場

• 摘要
• 基因生物標記
• 蛋白質生物標記物

第 6 章癌症/腫瘤分析市場：依癌症類型評估

• 摘要
• 乳癌
• 大腸癌
• 肺癌
• 攝護腺癌
• 淋巴瘤
• 白血病
• 子宮頸癌
• 其他癌症

第 7 章透過技術評估癌症/腫瘤分析市場

• 摘要
• 次世代定序儀 (NGS)
• 聚合□鍊式反應 (PCR)
• 原位雜交 (ISH)
• 免疫組織化學 (IHC)
• 其他技術

第 8 章癌症/腫瘤分析市場：應用評估

• 摘要
• 調查申請
• 臨床應用

第 9 章癌症/腫瘤分析市場評估：按最終使用者

• 摘要
• 製藥/生物製藥公司
• 醫院/診斷實驗室
• 學術/研究機構
• CRO（藥物開發合約組織）

第 10 章按地區劃分的癌症/腫瘤分析市場評估

• 摘要
• 北美
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 拉丁美洲
• 中東/非洲

第 11 章競爭分析

• 摘要
• 主要成長策略
• 競爭基準測試
• 市佔率分析（2022 年）
  • Thermo Fisher Scientific Inc.（美國）
  • Illumina, Inc.（美國）
  • F. Hoffmann-La Roche Ltd（瑞士）
  • Exact Sciences Corporation（美國）
  • Qiagen N.V.（荷蘭）
• 競爭對手儀表板
  • 行業領導者
  • 市場差異化因素
  • 領先企業
  • 新興公司

第 12 章公司簡介

• Thermo Fisher Scientific, Inc.
• Illumina, Inc.
• Qiagen N.V.
• F. Hoffmann-La Roche Ltd
• Exact Sciences Corporation
• Agilent Technologies, Inc.
• NanoString Technologies, Inc.
• HTG Molecular Diagnostics, Inc.
• Agendia Inc.
• Personalis, Inc.
• Tempus Labs, Inc.

第 13 章附錄

Cancer/Tumor Profiling Market by Biomarker Type (Genetic, Protein) Technology (NGS, PCR, ISH, IHC) Cancer Type (Breast, Lung, Colorectal, Prostate, Leukemia) Application (Clinical, Research) End User (Pharma, Academic, CRO)-Global Forecast to 2030

The global cancer/tumor profiling market is projected to reach $22.3 billion by 2030, at a CAGR of 20.9% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of the cancer/tumor profiling market is attributed to the increasing prevalence of cancer, the rising pharmaceutical R&D expenditures, the growing number of targeted therapies and the discovery of new actionable biomarkers, increasing investments in cancer research, the declining costs of NGS-based profiling, and advancements in multi-omics tumor profiling. However, the high capital investments required for NGS setups and long turnaround times restrain the growth of this market.

Additionally, the increasing focus on developing personalized medicines and the rising awareness and adoption of targeted therapies are expected to generate market growth opportunities. However, the lack of genetic experts for interpreting results, the non-availability of in-house tumor profiling technologies, and the high number of false biomarker discoveries are major challenges for the stakeholders in the cancer/tumor profiling market.

Based on biomarker type, in 2023, the genetic biomarkers segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the effectiveness of genetic biomarkers as targets for therapeutic treatments, their role in enhancing treatment delivery, and their utility in facilitating convenient disease diagnosis.

Based on technology, in 2023, the next-generation sequencing (NGS) segment is expected to account for the largest share of the market. The large market share of the segment is attributed to the growing adoption of NGS in cancer/tumor profiling, its ability to provide faster and more accurate genetic testing, the rapidly declining cost of sequencing per base, and the introduction of cost-effective benchtop laboratory sequencers.

Based on cancer type, the cancer/tumor profiling market is segmented into breast cancer, colorectal cancer, lung cancer, prostate cancer, lymphoma, leukemia, cervical cancer, and other cancer types. In 2023, the breast cancer segment is expected to account for the largest share of the cancer/tumor profiling market. The increase in breast cancer cases, government initiatives promoting breast cancer treatment, increasing healthcare expenditure, and reimbursement for certain profiling technologies such as NGS have propelled the demand for cancer/tumor profiling for breast cancer.

Based on application, the research applications segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the rising incidence of cancer, the growing demand for precision medicine, the increased discovery of biomarkers, and the availability of cost-effective advanced profiling technologies like NGS and PCR for research applications.

Based on end user, in 2023, the pharmaceutical & biopharmaceutical companies segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the declining costs of sequencing, the development of companion diagnostics and precision medicine, and the high demand for cancer/tumor profiling from pharmaceutical and biopharmaceutical companies, primarily for biomarker discovery purposes.

An in-depth analysis of the geographical scenario of the global cancer/tumor profiling market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the cancer/tumor profiling market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America's significant market share can be attributed to factors such as the rising burden of cancer, the presence of key market players, well-established healthcare infrastructure, and government initiatives aimed at bolstering cancer research efforts.

The key players operating in the global cancer/tumor profiling market are Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), NanoString Technologies, Inc. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), Agendia Inc. (U.S.), Personalis, Inc. (U.S.), Exact Sciences Corporation (U.S.), and Tempus Labs, Inc. (U.S.).

Scope of the Report:

Cancer/Tumor Profiling Market Assessment-by Biomarker Type

• Protein Biomarkers
• Genetic Biomarkers

Cancer/Tumor Profiling Market Assessment-by Technology

• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• In-situ hybridization (ISH)
• Immunohistochemistry (IHC)
• Other Technologies

Note: Other technologies include immunoassays, microarrays, mass spectrometers, Sanger sequencing, pyrosequencing, and fragment analysis

Cancer/Tumor Profiling Market Assessment-by Application

• Clinical Applications
• Research Applications

Cancer/Tumor Profiling Market Assessment-by Cancer Type

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Lymphoma
• Leukemia
• Cervical Cancer
• Other Cancer Types

Note: Other cancer types include bladder cancer, melanoma, kidney cancer, stomach cancer, ovarian cancer, thyroid cancer, and head & neck cancers

Cancer/Tumor Profiling Market Assessment-by End User

• Pharmaceutical & Biopharmaceutical Companies
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Contract Research Organizations (CROs)

Cancer/Tumor Profiling Market Assessment-by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • Italy
  • U.K.
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• 1.1. Market Definition and Scope
• 1.2. Market Ecosystem
• 1.3. Currency and Limitation
• 1.4. Key Stakeholders

2. Research Methodology

• 2.1. Research Approach
• 2.2. Process of Data Collection and Validation
  • 2.2.1. Secondary Research
  • 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
• 2.3. Market Sizing and Forecast
  • 2.3.1. Market Size Estimation Approach
  • 2.3.2. Growth Forecast Approach
  • 2.3.3. Market Share Analysis
• 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

• 4.1. Overview
• 4.2. Factors Affecting Market Growth
  • 4.2.1. Impact Analysis of Market Dynamics
  • 4.2.2. Factor Analysis
• 4.3. Regulatory Analysis
  • 4.3.1. North America
    • 4.3.1.1. U.S.
    • 4.3.1.2. Japan
    • 4.3.1.3. India
    • 4.3.1.4. Canada
  • 4.3.2. Europe
  • 4.3.3. Asia-Pacific
    • 4.3.3.1. China
    • 4.3.3.2. Japan
    • 4.3.3.3. India
  • 4.3.4. Latin America
  • 4.3.5. Middle East
• 4.4. Porter's Five Forces Analysis
  • 4.4.1. Bargaining Power of Buyers
  • 4.4.2. Bargaining Power of Suppliers
  • 4.4.3. Threat of Substitutes
  • 4.4.4. Threat of New Entrants
  • 4.4.5. Degree of Competition

5. Cancer/Tumor Profiling Market Assessment-by Biomarker Type

• 5.1. Overview
• 5.2. Genetic Biomarkers
• 5.3. Protein Biomarkers

6. Cancer/Tumor Profiling Market Assessment-by Cancer Type

• 6.1. Overview
• 6.2. Breast Cancer
• 6.3. Colorectal Cancer
• 6.4. Lung Cancer
• 6.5. Prostate Cancer
• 6.6. Lymphoma
• 6.7. Leukemia
• 6.8. Cervical Cancer
• 6.9. Other Cancer Types

7. Cancer/Tumor Profiling Market Assessment-by Technology

• 7.1. Overview
• 7.2. Next-Generation Sequencing (NGS)
• 7.3. Polymerase Chain Reaction (PCR)
• 7.4. In Situ Hybridization (ISH)
• 7.5. Immunohistochemistry (IHC)
• 7.6. Other Technologies

8. Cancer/Tumor Profiling Market Assessment-by Application

• 8.1. Overview
• 8.2. Research Applications
• 8.3. Clinical Applications

9. Cancer/Tumor Profiling Market Assessment-by End User

• 9.1. Overview
• 9.2. Pharmaceutical & Biopharmaceutical Companies
• 9.3. Hospitals & Diagnostic Laboratories
• 9.4. Academic & Research Institutes
• 9.5. Contract Research Organizations (CROs)

10. Cancer/Tumor Profiling Market Assessment-by Geography

• 10.1. Overview
• 10.2. North America
  • 10.2.1. U.S.
  • 10.2.2. Canada
• 10.3. Europe
  • 10.3.1. Germany
  • 10.3.2. France
  • 10.3.3. U.K.
  • 10.3.4. Italy
  • 10.3.5. Spain
  • 10.3.6. Rest of Europe
• 10.4. Asia-Pacific
  • 10.4.1. China
  • 10.4.2. Japan
  • 10.4.3. India
  • 10.4.4. Rest of Asia-Pacific
• 10.5. Latin America
• 10.6. Middle East & Africa

11. Competition Analysis

• 11.1. Overview
• 11.2. Key Growth Strategies
• 11.3. Competitive Benchmarking
• 11.4. Market Share Analysis (2022)
  • 11.4.1. Thermo Fisher Scientific Inc. (U.S.)
  • 11.4.2. Illumina, Inc. (U.S.)
  • 11.4.3. F. Hoffmann-La Roche Ltd (Switzerland)
  • 11.4.4. Exact Sciences Corporation (U.S.)
  • 11.4.5. Qiagen N.V. (Netherlands)
• 11.5. Competitive Dashboard
  • 11.5.1. Industry Leaders
  • 11.5.2. Market Differentiators
  • 11.5.3. Vanguards
  • 11.5.4. Emerging Companies

12. Company Profiles

• 12.1. Thermo Fisher Scientific, Inc.
• 12.2. Illumina, Inc.
• 12.3. Qiagen N.V.
• 12.4. F. Hoffmann-La Roche Ltd
• 12.5. Exact Sciences Corporation
• 12.6. Agilent Technologies, Inc.
• 12.7. NanoString Technologies, Inc.
• 12.8. HTG Molecular Diagnostics, Inc.
• 12.9. Agendia Inc.
• 12.10. Personalis, Inc.
• 12.11. Tempus Labs, Inc.

13. Appendix

• 13.1. Available Customization
• 13.2. Related Reports

• Table 1 Major Targeted Therapies and Corresponding Biomarkers
• Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
• Table 3 Regulatory Authorities Governing In Vitro Diagnostics, by Country/Region
• Table 4 Global Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 5 Germline Mutations in Hereditary Cancer Syndromes: Cancer-Causing Genes as Biomarkers of Risk
• Table 6 Global Cancer/Tumor Profiling Market for Genetic Biomarkers, by Country/Region, 2021-2030 (USD Million)
• Table 7 Global Cancer/Tumor Profiling Market for Protein Biomarkers, by Country/Region, 2021-2030 (USD Million)
• Table 8 Global Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD MILLION)
• Table 9 Number of New Breast Cancer Cases Globally (2020-2035)
• Table 10 Global Cancer/Tumor Profiling Market for Breast Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 11 Global Cancer/Tumor Profiling Market for Colorectal Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 12 Global Cancer/Tumor Profiling Market for Lung Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 13 Number of New Prostate Cancer Cases (2020-2035)
• Table 14 Global Cancer/Tumor Profiling Market for Prostate Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 15 Number of New Non-Hodgkin Lymphoma Cancer Cases (2020-2035)
• Table 16 Global Cancer/Tumor Profiling Market for Lymphoma, by Country/Region, 2021-2030 (USD Million)
• Table 17 Estimated Number of New Leukemia Cases (2020-2035)
• Table 18 Global Cancer/Tumor Profiling Market for Leukemia, by Country/Region, 2021-2030 (USD Million)
• Table 19 Global Cancer/Tumor Profiling Market for Cervical Cancer, by Country/Region, 2021-2030 (USD Million)
• Table 20 Number of New Cancer Cases (2020-2035)
• Table 21 Global Cancer/Tumor Profiling Market for Other Cancer Types, by Country/Region, 2021-2030 (USD Million)
• Table 22 Global Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 23 Global Next-Generation Sequencing (NGS) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 24 Global Polymerase Chain Reaction (PCR) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 25 Global In Situ Hybridization Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 26 Applications of IHC in Oncology and Related Antibodies
• Table 27 Global Immunohistochemistry (IHC) Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 28 Global Other Technologies Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 29 Global Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 30 Currently Available Targeted Therapies and Corresponding Biomarkers
• Table 31 Global Cancer/Tumor Profiling Market for Research Applications, by Country/Region, 2021-2030 (USD Million)
• Table 32 Frequently Used Clinical Tumor Markers
• Table 33 Global Cancer/Tumor Profiling Market for Clinical Applications, by Country/Region, 2021-2030 (USD Million)
• Table 34 Global Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 35 Global Cancer/Tumor Profiling Market for Pharmaceutical & Biopharmaceutical Companies, by Country/Region, 2021-2030 (USD Million)
• Table 36 Global Cancer/Tumor Profiling Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2021-2030 (USD Million)
• Table 37 Global Cancer/Tumor Profiling Market for Academic & Research Institutes, by Country/Region, 2021-2030 (USD Million)
• Table 38 Global Cancer/Tumor Profiling Market for CROs, by Country/Region, 2021-2030 (USD Million)
• Table 39 Global Cancer/Tumor Profiling Market, by Region, 2021-2030 (USD Million)
• Table 40 Estimated Cancer Cases in North America: 2020-2030
• Table 41 North America: Cancer/Tumor Profiling Market, by Country, 2021-2030 (USD Million)
• Table 42 North America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 43 North America: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 44 North America: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 45 North America: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 46 North America: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 47 U.S.: Key Macro & Micro Indicators
• Table 48 U.S.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 49 U.S.: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 50 U.S.: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 51 U.S.: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 52 U.S.: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 53 Canada: Key Macro & Micro Indicators
• Table 54 Canada: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 55 Canada: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 56 Canada: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 57 Canada: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 58 Canada: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 59 Europe: Cancer/Tumor Profiling Market, by Country, 2021-2030 (USD Million)
• Table 60 Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 61 Europe: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 62 Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 63 Europe: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 64 Europe: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 65 Germany: Key Macro & Micro Indicators
• Table 66 Germany: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 67 Germany: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 68 Germany: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 69 Germany: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 70 Germany: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 71 France: Key Macro & Indicators
• Table 72 France: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 73 France: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 74 France: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 75 France: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 76 France: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 77 U.K.: Key Macro & Micro Indicators
• Table 78 U.K.: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 79 U.K.: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 80 U.K.: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 81 U.K.: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 82 U.K.: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 83 Italy: Key Macro & Micro Indicators
• Table 84 Italy: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 85 Italy: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 86 Italy: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 87 Italy: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 88 Italy: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 89 Spain: Key Macro & Micro Indicators
• Table 90 Spain: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 91 Spain: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 92 Spain: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 93 Spain: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 94 Spain: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 95 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
• Table 96 Rest of Europe: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 97 Rest of Europe: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 98 Rest of Europe: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 99 Rest of Europe: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 100 Rest of Europe: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 101 Asia-Pacific: Cancer/Tumor Profiling Market, by Country/Region, 2021-2030 (USD Million)
• Table 102 Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 103 Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 104 Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 105 Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 106 Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 107 China: Key Macro & Micro Indicators
• Table 108 China: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 109 China: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 110 China: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 111 China: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 112 China: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 113 Japan: Key Macro & Micro Indicators
• Table 114 Japan: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 115 Japan: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 116 Japan: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 117 Japan: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 118 Japan: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 119 India: Key Macro & Micro Indicators
• Table 120 India: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 121 India: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 122 India: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 123 India: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 124 India: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 125 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
• Table 126 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 127 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 128 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 129 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 130 Rest of Asia-Pacific: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 131 Latin America: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 132 Latin America: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 133 Latin America: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 134 Latin America: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 135 Latin America: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 136 Middle East & Africa: Cancer/Tumor Profiling Market, by Biomarker Type, 2021-2030 (USD Million)
• Table 137 Middle East & Africa: Cancer/Tumor Profiling Market, by Technology, 2021-2030 (USD Million)
• Table 138 Middle East & Africa: Cancer/Tumor Profiling Market, by Cancer Type, 2021-2030 (USD Million)
• Table 139 Middle East & Africa: Cancer/Tumor Profiling Market, by Application, 2021-2030 (USD Million)
• Table 140 Middle East & Africa: Cancer/Tumor Profiling Market, by End User, 2021-2030 (USD Million)
• Table 141 Recent Developments, by Company, 2020-2023